Tetrachlorodecaoxide
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.101.959 |
| (verify) | |
"Tetrachlorodecaoxide" (TCDO) is a chlorite-containing substance with claimed immunomodulatory, macrophage-activating properties.[1] WF10 (Macrokine, Immunokine, Oxoferin) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection.[2] Tetrachlorodecaoxide/WF10 were originally developed by Oxo Chemie.[3] The chemical formula is given as Cl4H2O114-.[4][2] This incomplete formula shows a mixture of chlorite ion, water, and molecular oxygen: "Cl4H2O114-" = 4ClO2− + H2O + O2. Oxoferin was found to be equivalent with aqueous sodium chlorite.[5]
Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis,[6] is effective in the treatment of diabetic foot ulcers,[7] and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.[8]
References
[edit]- ^ Maraprygsavan P, Mongkolsuk J, Arnhold J, Kuehne FW (June 2016). "The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome". Journal of Clinical & Translational Endocrinology. 4: 53–58. doi:10.1016/j.jcte.2016.05.001. PMC 5680448. PMID 29159131.
- ^ a b "WF10". Drugprofiles.informa.com. Retrieved 2016-12-20.
- ^ "About Us". OXO Chemie (Thai). Archived from the original on 2016-12-20. Retrieved 2016-12-20.
- ^ "Tetrachlorodecaoxide - Cl4H2O11-4". PubChem. U.S. National Library of Medicine. Retrieved 2016-12-20.
- ^ Habermann E, Müller B (Jan 1989). "Oxoferin und Natriumchlorit — Ein Vergleich" [Oxoferin and sodium chlorite — a comparison]. Klinische Wochenschrift (in German). 67 (1): 20–25. doi:10.1007/bf01736530. PMID 2921839.
- ^ Smit SG, Heyns CF (April 2010). "Management of radiation cystitis" (PDF). Nature Reviews. Urology. 7 (4): 206–14. doi:10.1038/nrurol.2010.23. hdl:10019.1/14211. PMID 20212517. S2CID 29208541.
- ^ Yingsakmongkol N (March 2013). "Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers". Journal of Wound Care. 22 (3): 130–2, 134–6. doi:10.12968/jowc.2013.22.3.130. PMID 23665731.
- ^ Parikh R, Bakhshi G, Naik M, Gaikwad B, Jadhav K, Tayade M (September 2016). "The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing". Archives of Plastic Surgery. 43 (5): 395–401. doi:10.5999/aps.2016.43.5.395. PMC 5040840. PMID 27689045.